Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer : OlympiAD
Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: Presence of a germline BRCA1 and/or BRCA2 mutation (gBRCAm) may sensitize tumors to poly(ADP-ribose) polymerase (PARP) inhibition via inactivation of the second allele, resulting in gene-specific loss of heterozygosity (gsLOH) and homologous recombination deficiency (HRD). Here we explore whether tissue sample testing provides an additional route to germline testing to inform treatment selection for PARP inhibition.
PATIENTS AND METHODS: In this prespecified exploratory analysis, BRCA1 and/or BRCA2 mutations in blood samples (gBRCAm) and tumor tissue (tBRCAm) were analyzed from patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer and known gBRCAm, enrolled in the phase III OlympiAD trial. The frequency and nature of tBRCAm, HRD score status [HRD-positive (score ≥42) versus HRD-negative (score <42) using the Myriad myChoice® CDx test] and rates of gsLOH were determined, and their impact on clinical efficacy (objective response rate and progression-free survival) was explored.
RESULTS: Tissue samples from 161/302 patients yielded tBRCAm, HRD and gsLOH data for 143 (47%), 129 (43%) and 125 (41%) patients, respectively. Concordance between gBRCAm and tBRCAm was 99%. gsLOH was observed in 118/125 (94%) patients [BRCA1m, 73/76 (96%); BRCA2m, 45/49 (92%)]. A second mutation event was recorded for two of the three BRCA1m patients without gsLOH. The incidence of HRD-negative was 16% (21/129) and was more common for BRCA2m (versus BRCA1m) and/or for hormone receptor-positive (versus triple-negative) disease. Olaparib antitumor activity was observed irrespective of HRD score.
CONCLUSIONS: gBRCAm identified in patients with HER2-negative metastatic breast cancer by germline testing in blood was also identified by tumor tissue testing. gsLOH was common, indicating a high rate of biallelic inactivation in metastatic breast cancer. Olaparib activity was seen regardless of gsLOH status or HRD score. Thus, additional tumor testing to inform PARP inhibitor treatment selection may not be supported for these patients.
Errataetall: |
CommentIn: Ann Oncol. 2021 Dec;32(12):1460-1462. - PMID 34678412 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
---|---|
Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 32(2021), 12 vom: 15. Dez., Seite 1582-1589 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hodgson, D [VerfasserIn] |
---|
Links: |
---|
Themen: |
BRCA1 Protein |
---|
Anmerkungen: |
Date Completed 26.11.2021 Date Revised 31.05.2022 published: Print-Electronic CommentIn: Ann Oncol. 2021 Dec;32(12):1460-1462. - PMID 34678412 Citation Status MEDLINE |
---|
doi: |
10.1016/j.annonc.2021.08.2154 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM330423029 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM330423029 | ||
003 | DE-627 | ||
005 | 20231225211243.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.annonc.2021.08.2154 |2 doi | |
028 | 5 | 2 | |a pubmed24n1101.xml |
035 | |a (DE-627)NLM330423029 | ||
035 | |a (NLM)34500047 | ||
035 | |a (PII)S0923-7534(21)04458-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hodgson, D |e verfasserin |4 aut | |
245 | 1 | 0 | |a Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer |b OlympiAD |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.11.2021 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a CommentIn: Ann Oncol. 2021 Dec;32(12):1460-1462. - PMID 34678412 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. | ||
520 | |a BACKGROUND: Presence of a germline BRCA1 and/or BRCA2 mutation (gBRCAm) may sensitize tumors to poly(ADP-ribose) polymerase (PARP) inhibition via inactivation of the second allele, resulting in gene-specific loss of heterozygosity (gsLOH) and homologous recombination deficiency (HRD). Here we explore whether tissue sample testing provides an additional route to germline testing to inform treatment selection for PARP inhibition | ||
520 | |a PATIENTS AND METHODS: In this prespecified exploratory analysis, BRCA1 and/or BRCA2 mutations in blood samples (gBRCAm) and tumor tissue (tBRCAm) were analyzed from patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer and known gBRCAm, enrolled in the phase III OlympiAD trial. The frequency and nature of tBRCAm, HRD score status [HRD-positive (score ≥42) versus HRD-negative (score <42) using the Myriad myChoice® CDx test] and rates of gsLOH were determined, and their impact on clinical efficacy (objective response rate and progression-free survival) was explored | ||
520 | |a RESULTS: Tissue samples from 161/302 patients yielded tBRCAm, HRD and gsLOH data for 143 (47%), 129 (43%) and 125 (41%) patients, respectively. Concordance between gBRCAm and tBRCAm was 99%. gsLOH was observed in 118/125 (94%) patients [BRCA1m, 73/76 (96%); BRCA2m, 45/49 (92%)]. A second mutation event was recorded for two of the three BRCA1m patients without gsLOH. The incidence of HRD-negative was 16% (21/129) and was more common for BRCA2m (versus BRCA1m) and/or for hormone receptor-positive (versus triple-negative) disease. Olaparib antitumor activity was observed irrespective of HRD score | ||
520 | |a CONCLUSIONS: gBRCAm identified in patients with HER2-negative metastatic breast cancer by germline testing in blood was also identified by tumor tissue testing. gsLOH was common, indicating a high rate of biallelic inactivation in metastatic breast cancer. Olaparib activity was seen regardless of gsLOH status or HRD score. Thus, additional tumor testing to inform PARP inhibitor treatment selection may not be supported for these patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a PARP inhibitor | |
650 | 4 | |a gBRCAm | |
650 | 4 | |a tumor tissue testing | |
650 | 7 | |a BRCA1 Protein |2 NLM | |
650 | 7 | |a BRCA1 protein, human |2 NLM | |
650 | 7 | |a BRCA2 Protein |2 NLM | |
650 | 7 | |a BRCA2 protein, human |2 NLM | |
650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
700 | 1 | |a Lai, Z |e verfasserin |4 aut | |
700 | 1 | |a Dearden, S |e verfasserin |4 aut | |
700 | 1 | |a Barrett, J C |e verfasserin |4 aut | |
700 | 1 | |a Harrington, E A |e verfasserin |4 aut | |
700 | 1 | |a Timms, K |e verfasserin |4 aut | |
700 | 1 | |a Lanchbury, J |e verfasserin |4 aut | |
700 | 1 | |a Wu, W |e verfasserin |4 aut | |
700 | 1 | |a Allen, A |e verfasserin |4 aut | |
700 | 1 | |a Senkus, E |e verfasserin |4 aut | |
700 | 1 | |a Domchek, S M |e verfasserin |4 aut | |
700 | 1 | |a Robson, M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 32(2021), 12 vom: 15. Dez., Seite 1582-1589 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
773 | 1 | 8 | |g volume:32 |g year:2021 |g number:12 |g day:15 |g month:12 |g pages:1582-1589 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2021.08.2154 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 32 |j 2021 |e 12 |b 15 |c 12 |h 1582-1589 |